[Special Stock] IMBDX Penetrates Global Liquid Biopsy 100 Trillion Market... 'Level Up' Through Overseas Expansion

IMBDX is showing strong performance. Securities firms' analysis that the company will begin penetrating the global liquid biopsy-based early cancer diagnosis market, valued at approximately 100 trillion KRW, through its 'CancerFind' product launched in November last year appears to be influencing its stock price.

As of 10:20 AM on the 24th, IMBDX was trading at 18,170 KRW, up 2,860 KRW (18.68%) compared to the previous trading day.

SK Securities expects improved investment sentiment in the pharmaceutical and bio sectors due to expectations of interest rate cuts and forecasts that various growth momentum for IMBDX will become visible from the second half of this year.

Researcher Heo Seon-jae of SK Securities analyzed, "CancerFind is a multi-cancer early diagnosis platform that can simultaneously test for eight types of cancer?colon, stomach, liver, pancreas, lung, breast, ovary, and prostate?through a single blood test." He added, "As a 'fast follower' in the liquid biopsy market, it has secured sufficient reliability in its technology by obtaining clinical results, publications, registration in national cancer conquest projects, and approval from the Korea Disease Control and Prevention Agency," and noted, "As of the first quarter of this year, it has been commercialized in 10 major general hospitals in Korea."

Researcher Heo also expressed expectations that "this year, the number of applicable cancer types will expand from 8 to 20," and "the price will be reduced from 1 million KRW to 300,000 KRW through cost structure improvements."

CancerFind is also pursuing overseas expansion into Europe, Japan, Southeast Asia, and the Middle East. Leading companies such as Grail and Exact Sciences have been recognized with corporate valuations ranging from 10 trillion to 12.5 trillion KRW.

IMBDX is reportedly in discussions for a contract with the global pharmaceutical company AstraZeneca. Kim Tae-yu, CEO of IMBDX, recently explained in an interview with the media, "Besides the existing contracted drug with AstraZeneca, there are about 30 targeted therapies, and discussions are underway to further expand collaboration on each of these drugs."

CEO Kim Tae-yu, who founded IMBDX, and Professor Bang Doo-hee of Yonsei University's Department of Chemistry are top authorities in their respective fields. CEO Kim is a leading expert in oncology in Korea, having served as director of the Cancer Hospital at Seoul National University Hospital, head of the Precision Medicine Center, and president of the Korean Society of Medical Oncology. Professor Bang is a distinguished scholar in the industry who has hands-on experience and development expertise in NGS (Next Generation Sequencing) technology from Harvard University in the United States.